Eosinophilic Granulomatosis With Polyangiitis Following COVID-19Vaccination: A Case Report
10.3346/jkms.2023.38.e382
- Author:
Yu-Kyoung HWANG
1
;
Hui-Hwan KWAK
;
Jeong-Eun YUN
;
Sae-Hoon KIM
;
Yoon-Seok CHANG
Author Information
1. Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- Publication Type:Case Report
- From:Journal of Korean Medical Science
2023;38(48):e382-
- CountryRepublic of Korea
- Language:English
-
Abstract:
The current emergence of the coronavirus disease 2019 (COVID-19) pandemic and the possible side effects of COVID-19 mRNA vaccination remain worrisome. Few cases of vaccination-related side effects, such as vasculitis, have been reported. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a type of vasculitis characterized by the histological richness of eosinophils, asthma, polyneuropathy, sinusitis, and skin or lung involvement. Here, we report the first case of new onset EGPA following COVID-19 vaccination in Korea. A 71-year old woman developed a skin rash and presented with progressive weakness of the upper and lower extremities after the BNT162b2 vaccination (Pfizer-BioNTech). She was diagnosed with EGPA and her symptoms improved after systemic steroid and immunosuppressant therapy. Although it is very rare, clinicians should be aware that EGPA may occur after COVID-19 vaccination.
